Intrauterine system
View Patent ↗An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.
1. An intrauterine system for use in the treatment of a medical condition selected from the group consisting of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy, the system comprising: a deposit of a therapeutically effective dose of a biologically active compound, wherein the deposit is substantially form stable and is not eroded during use; a frame defining an interior space for receipt of the deposit, the frame having an open structure that extends longitudinally along the frame and wherein the frame is surrounding the deposit while allowing access to a substantial part of an outer surface of the deposit; and one or more retention elements for retaining the frame within the uterus of a female mammal.
2. The system according to claim 1 , wherein the frame is generally flexible and interacts with the deposit to form a mechanical structure having a bending stiffness greater than the sum of that of the frame and deposit taken individually.
3. The system according to claim 1 , wherein the deposit is a rod shaped deposit located in a stem portion of the frame, and the deposit has a bending stiffness that is greater than that of the stem portion of the frame itself.
4. The system according to any preceding claim, wherein the deposit comprises a polymer matrix core surrounded by a rate controlling membrane.
5. The system according to any preceding claim, wherein the compound is a hormone, an anti-hormone or a hormone with a mixed profile such as a partial agonist, a partial antagonist, or a combination thereof.
6. The system according to claim 5 , wherein the hormone, anti-hormone or hormone with a mixed profile comprises a progesterone receptor agonist, a progesterone receptor antagonist, or a mixed-profile progesterone receptor ligand.
7. The system according to claim 6 , wherein the mixed-profile progesterone receptor ligand is a selective progesterone receptor modulator (SPRM).
8. The system according to claim 5 , wherein the hormone, anti-hormone or hormone with a mixed profile comprises an estrogen receptor agonist, an estrogen receptor antagonist, or a mixed-profile estrogen receptor ligand.
9. The system according to claim 6 , wherein the mixed-profile estrogen receptor ligand is a selective estrogen receptor modulator (SERM).
10. The system according to claim 1 , wherein the compound has estrogen receptor modulating activity and is selected from the group consisting of 17beta-estradiol, estriol, conjugated equine estrogens, estrogen receptor alpha selective agonists alone or in combination with a progestogen, tamoxifen or active metabolites thereof, fulvestrant, compounds blocking the new formation of estradiol.
11. The system according to claim 10 , wherein the compounds blocking the new formation of estradiol are aromatase inhibitors selected from the group consisting of anastrozole, letrozole and exemestane.
12. The system according to claim 5 , wherein the hormone, anti-hormone or hormone with a mixed profile comprises a compound with androgen receptor modulating activity selected form the group consisting of an androgen receptor agonist, an androgen receptor antagonist and a mixed-profile androgen receptor ligand.
13. The system according to claim 1 , wherein the therapeutically effective dose of a biologically active compound comprises a non-hormonal compound.
14. The system according to claim 1 , wherein the therapeutically effective dose of a biologically active compound comprises a non-steroidal hormone.
15. The system according to claim 1 , wherein the frame has an open structure allowing access to at least 50% of the outer surface of the deposit.
16. A method for the manufacture of an intrauterine system comprising: forming a frame having an interior space and an open structure that extends longitudinally along the frame and wherein the frame is surrounding the deposit while allowing access to a substantial part of an outer surface of the deposit; forming one or more retention elements for retaining the frame within the uterus of a female mammals; providing a deposit of a therapeutically effective dose of a biologically active compound for the treatment of a medical condition selected from the group consisting of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy, having an outer surface provided with a rate controlling structure, wherein the deposit is substantially form stable and is not eroded during use; and inserting the deposit into the interior space such that a substantial part of the outer surface is exposed through the open structure.
17. The method according to claim 16 , further comprising forming the deposit by co-extrusion of a polymer matrix core containing the compound and a rate controlling membrane.
18. A method of treating a female mammal having a medical condition selected from the group consisting of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy, the method comprising placing in the uterus of the mammal the intrauterine system according to claim 1 .